Riskpilot← Back to searchSign inGet full accessZYMENEX ApS
APSDissolvedCVR 27394752Langelinie Allé 35Forskning og eksperimentel udvikling indenfor bioteknologi · NACE 721100Est. 20031 employees
Revenue 2018
DKK 10,8M
-73% vs 2017
EBITDA margin
12.7%
-50% vs 2017
Equity ratio
51.6%
Financial strength
Net profit 2018
DKK 1,3M
-62% vs 2017
| Revenue | DKK 10,8M | -73% |
| EBITDA | DKK 1,4M | -50% |
| Net profit | DKK 1,3M | -62% |
| Total assets | DKK 160,1M | -5% |
| Equity | DKK 82,6M | +2% |
| Employees | 1 | — |
Legal name
ZYMENEX ApS
CVR number
27394752
Legal form
Anpartsselskab
NACE code
721100 · Forskning og eksperimentel udvikling indenfor bioteknologi
Founded
14. oktober 2003
Share capital
DKK 2.500.000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2018-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Address
Langelinie Allé 35
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | -67.882 | -52.501 | 49.052 | 39.575 | 10.758 |
| Staff expenses | -6.448 | -7.883 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -40.261 | -33.236 | 5.131 | 3.573 | 337.318 | 2.747 | 1.364 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -40.261 | -33.236 | 5.131 | 3.573 | 337.318 | 2.747 | 1.364 |
| Net financials | -1.777 | -2.781 | -4.065 | -3.574 | -2.787 | 4.686 | 274 |
| Profit before tax | -42.038 | -36.017 | 1.066 | -2 | 334.531 | 7.433 | 1.638 |
| Tax | -0 | -2.259 | -0 | -658 | 40.171 | 4.029 | 346 |
| Net profit | -42.038 | -33.758 | 1.066 | 656 | 294.360 | 3.404 | 1.292 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|---|---|---|
| Total assets | 4.221 | 5.100 | 18.486 | 17.954 | 360.029 | 168.416 | 160.123 |
| Equity | -32.064 | -65.822 | -64.756 | -64.100 | 230.260 | 80.885 | 82.550 |
| Long-term debt | 29.304 | 58.430 | 70.470 | 74.364 | 69.046 | 72.686 | 70.191 |
| Short-term debt | 6.981 | 12.492 | 12.772 | 7.690 | 60.723 | 14.845 | 7.382 |
| Total debt | 36.285 | 70.922 | 83.242 | 82.054 | 129.769 | 87.531 | 77.573 |
EBITDA margin
12.7%
This company
15.8%
Market median
-20% vs market
20122018
Equity ratio
51.6%
This company
38.2%
Market median
+35% vs market
20122018
Return on equity
1.6%
This company
18.4%
Market median
-91% vs market
20122018
Net profit margin
12.0%
This company
8.1%
Market median
+48% vs market
20122018
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
20122018
Debt / equity
0.94×
This company
0.62×
Market median
+52% vs market
20122018
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PP Management | Management | 2015 | — | — |
NT Management | Management | 2019 | — | — |
KS Management | Management | 2003 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2004 | — | — | |
| Chairman | 2015 | — | — | |
| Board of Directors | 2013 | — | — | |
| Chairman | 2003 | — | — | |
| Board of Directors | 2015 | — | — | |
| Chairman | 2014 | — | — | |
| Board of Directors | 2006 | — | — | |
| Chairman | 2013 | — | — | |
| Chairman | 2019 | — | — | |
| Chairman | 2005 | — | — | |
| Chairman | 2007 | — | — | |
| Board of Directors | 2015 | — | — | |
| Chairman | 2004 | — | — | |
| Board of Directors | 2003 | — | — | |
| Board of Directors | 2014 | — | — | |
| Chairman | 2010 | — | — | |
| Board of Directors | 2006 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
ZYMENEX HOLDING ApS | Company | 100.0% | 100.0% | 2005 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ZYMENEX ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Paolo Patri | Management | 0 companies |
| Nina Teerés Herne | Management | 0 companies |
| Klaus Søgaard | Management | 0 companies |
| Ron Cohen | Board of Directors | 0 companies |
| Jens Morten Fogh | Chairman | 0 companies |
| Paolo Patri | Board of Directors | 0 companies |
| Jan-Erik Gunnar Svensson | Chairman | 0 companies |
| Natallia Misuna | Board of Directors | 0 companies |
| Mark Parry-Billings | Chairman | 0 companies |
| Per Toft Valstorp | Board of Directors | 0 companies |
| Andrew Philip Dickinson | Chairman | 0 companies |
| Mark Parry-Billings | Chairman | 0 companies |
| Jan Honoré | Chairman | 0 companies |
| Thomas Tscherning | Chairman | 0 companies |
| Claes Magnus Andersson | Board of Directors | 0 companies |
| Fredric David Price | Chairman | 0 companies |
| Niels Thomas Heering | Board of Directors | 0 companies |
| Danilo Piroli | Board of Directors | 0 companies |
| Sten Verland | Chairman | 0 companies |
| Bo Jesper Hansen | Board of Directors | 0 companies |